METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Chart
Direct answers, cited to the trial and lab record, to the questions readers most often bring to these three metabolic peptides.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide modeled on the C-terminal, fat-metabolism domain of human growth hormone (residues 177-191), with one amino acid substituted to aid manufacturing. It was developed as an anti-obesity drug candidate. It does not bind the growth hormone receptor, which is the basis for the claim that it avoids GH's growth-promoting effects [7]. It is not an approved medicine; it is sold only as a research chemical.
What does the peptide AOD9604 do?
In laboratory and animal studies, AOD9604 inhibits acetyl-CoA carboxylase, an enzyme involved in storing fat, and increases expression of the beta-3 adrenergic receptor in fat tissue, a combination associated with reduced fat synthesis and increased fat burning [4][7]. In the human obesity trial program, it did not produce a statistically significant weight-loss effect over placebo, so what it does in cells and rodents has not been confirmed as a human fat-loss effect.
Does AOD-9604 actually work?
For weight loss in humans: the published record does not support that it does. The pivotal human obesity trial program did not separate AOD-9604 from placebo on the weight-loss endpoint, and the development program was discontinued around 2007. Its safety and tolerability profile across roughly six trials in about 900 obese adults was indistinguishable from placebo [3] — which speaks to safety, not to efficacy. Community reports (anecdotal, not clinical evidence) largely echo this: the most common report is no noticeable fat loss.
How does AOD-9604 work?
Mechanistically, it works through two documented routes: inhibiting acetyl-CoA carboxylase via a membrane-derived second messenger, which slows new fat synthesis [7], and increasing beta-3 adrenergic receptor expression in fat tissue, which was shown in mice to be required for the chronic weight- and fat-reducing effect (the effect disappeared in beta-3 receptor knockout mice) [4]. Both mechanisms were characterized in cell and rodent systems; neither has been confirmed as the basis of a human fat-loss effect.
What does the MOTS-c peptide do?
MOTS-c is a peptide encoded inside the mitochondrial genome that activates AMPK, a cellular energy-sensing switch, primarily via effects in skeletal muscle, and directly binds casein kinase 2 (CK2) with tissue-specific effects — activating in muscle and suppressing in fat tissue [8][10]. In mouse studies it improved muscle glucose uptake, helped prevent muscle atrophy, and increased physical performance in aged animals [8][11]. No completed human efficacy trial of exogenous MOTS-c exists.
What are the negative side effects of MOTS-c?
There is no established human side-effect profile for MOTS-c, because no completed human efficacy or safety trial of administering it exists. The one substantial human data set is an observational cohort study in hemodialysis patients that measured naturally circulating MOTS-c levels and their association with cardiovascular and mortality risk — it did not involve giving anyone MOTS-c and does not describe side effects [9]. This desk does not carry catalogued anecdotal reports for MOTS-c and will not speculate on a side-effect profile the literature has not established.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any human use and is sold, where available, only as a research chemical for laboratory use — not as a supplement or medicine for human consumption. It is also treated by anti-doping authorities as a prohibited substance in elite sport. This page describes its regulatory and research status; it is not legal advice for any specific jurisdiction or use case.
How often do you inject MOTS-c?
This desk provides no injection schedule, dose, or administration guidance for MOTS-c or any other compound. No validated human pharmacokinetics exist for MOTS-c — no measured human half-life, bioavailability, or dose-response relationship has been published — so no injection frequency has clinical support. Any interval discussed in research-use communities is unverified anecdote, not a finding from a study.
What does retatrutide do?
Retatrutide activates three metabolic receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion; the glucagon arm is proposed to add energy expenditure through thermogenesis [13][14]. In a Phase 2 obesity trial, the highest dose produced a mean -24.2% body-weight change over 48 weeks, the largest Phase 2 figure reported for any incretin-class compound [16]. It is investigational and not approved for any use.
How does retatrutide work?
It engages GLP-1R, GIPR, and GCGR with deliberately uneven potency at each — roughly 8.9-fold above native GIP at the GIP receptor but well below native-hormone potency at the glucagon and GLP-1 receptors, per cryo-EM structural work [14]. The GLP-1/GIP arms reduce food intake and improve insulin secretion; the added glucagon-receptor activity is proposed to raise energy expenditure through brown-fat thermogenesis, working on both sides of the energy-balance equation at once [13].
How to reconstitute retatrutide?
This desk does not provide reconstitution, handling, or administration instructions for retatrutide or any other compound. Retatrutide is an investigational drug studied only under clinical-trial protocols; guidance for preparing or administering it outside that context is a safety and legal question this literature digest is not positioned to answer, and doing so would cross into the medical-advice territory this desk deliberately avoids.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any other regulator as of mid-2026. It is an investigational compound in Phase 3 clinical trials (the TRIUMPH program); all published efficacy and safety data come from Phase 1 and Phase 2 studies [13][16][17]. Material sold outside a registered clinical trial cannot be confirmed as authentic retatrutide, and the FDA issued more than 50 warning letters to vendors of retatrutide-labeled products in 2025 [13].